Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
Objective Behavioral rating scales that assess impairments in executive function commonly associated with attention-deficit/hyperactivity disorder (ADHD) may offer advantages over neuropsychological testing. The primary objective of this study was to evaluate the efficacy of lisdexamfetamine dimesylate for executive function deficits in adults with ADHD and clinically significant executive function impairment using self-reported Behavior Rating Inventory of Executive Function-Adult version (BRIEF-A) assessments. Method This randomized double-blind study, conducted between May 2010 and November 2010, screened at least 1 participant at 35 of 39 registered US clinical research sites. Adults (aged 18-55 years) with a primary ADHD diagnosis (meeting full DSM-IV-TR criteria) and executive function deficits (assessed by baseline BRIEF-A Global Executive Composite [GEC] T-scores of at least 65) were randomized to treatment with optimized lisdexamfetamine dimesylate (30 mg/d, 50 mg/d, or 70 mg/d; n = 80) or placebo (n = 81) during a 10-week double-blind treatment period. Outcome measures included the BRIEF-A scales (GEC, index, and clinical subscales). Results At week 10 or at early termination, lisdexamfetamine dimesylate was associated with significantly greater reductions from baseline in mean BRIEF-A GEC T-scores than placebo (effect size, 0.74; P Conclusion Among adults with ADHD and clinically significant executive function deficits, lisdexamfetamine dimesylate was associated wi…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At study end point, compared with baseline, all doses of LDX demonstrated significant improvements in ADHD Rating Scale Version-IV (ADHD-RS-IV) scores and in Clinical Global Impressions Improvement (CGI-I) scores, compared with placebo (P < .0001; P < .01, respectively).”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [22]
In the citing paper
“The first trial by Adler et al22 established the efficacy of LDX in adults and resulted in LDX being the first ADHD medication approved by the Food and Drug Administration (FDA) for adults in the United States.”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [22]
In the citing paper
“The efficacy and safety of once-daily LDX in adults (aged 18-55 years) diagnosed with ADHD according to Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision) criteria was demonstrated in short-term, randomized, double-blind, placebo-controlled multicenter studies incorporating a parallel-group22,23 or crossover design.24”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [22]
In the citing paper
“The most commonly reported adverse event in patients who received LDX during the short-term trials was a decrease in appetite, reported at 26.5%22 and 32.9%,23 although weight loss was not consistently reported in these trials.”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [22]
In the citing paper
“Other commonly reported adverse events were insomnia (11%-19%), and nausea (2.5%-12.5%).”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [22]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cited by
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2018.11.001 · Cited by 686
“The safety and tolerability profile is similar to other stimulants [240,241].”
BackgroundFaraone, S. V., Rostain, A. L., Blader, J., Busch, B., Childress, A. C., Connor, D. F., & Newcorn, J. H. (2019) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12899 · Cited by 400
Adult attention-deficit hyperactivity disorder: key conceptual issues
Asherson, P., Buitelaar, J., Faraone, S. V., & Rohde, L. A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30032-3 · Cited by 347
Associations of sleep disturbance with ADHD: implications for treatment
Hvolby, A. (2015) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0151-0 · Cited by 339
McElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2162 · Cited by 322
Metadata
- Authors
- Adler, L. A., Dirks, B., Deas, P. F., Raychaudhuri, A., Dauphin, M. R., Lasser, R. A., & Weisler, R. H.
- Affiliations
- VA NY Harbor Healthcare System (US)
- Corresponding author
- Adler, Lenard A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2013-07-15
- Volume
- 74
- Issue
- 07
- Pages
- 694-702
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1997255333
- Cited by
- 62
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 4 · 2018: 8 · 2017: 9 · 2016: 6 · 2015: 3 · 2014: 10 · 2013: 1
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, adult ADHD, executive dysfunction, BRIEF-A, behavior rating scales, metacognition, behavioral regulation, placebo comparison, treatment safety, dose comparison
- MeSH terms
- Lisdexamfetamine Dimesylate, Adult, Central Nervous System Stimulants, Attention, Attention Deficit Disorder with Hyperactivity, Behavioral Symptoms, Dextroamphetamine, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Psychiatric Status Rating Scales, Self-Assessment, Treatment Outcome, Drug Monitoring, Diagnostic and Statistical Manual of Mental Disorders, Executive Function
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.4088/jcp.12m08144
- The paper
- Adler, L. A., Dirks, B., Deas, P. F., Raychaudhuri, A., Dauphin, M. R., Lasser, R. A., & Weisler, R. H. (2013). Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.12m08144
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.